The Full Catalog

The most extensively researched performance supplement in existence with over 500 peer-reviewed studies. Increases muscle phosphocreatine stores to extend high intensity exercise capacity, accelerate strength gains, and support lean muscle development. Emerging evidence supports cognitive and neuroprotective benefits. Exceptionally safe profile validated across decades of research.

View Full Intel →

A naturally occurring hormone whose synthetic analogs — including semaglutide (Ozempic, Wegovy) and liraglutide — have become among the most prescribed medications in the world. FDA approved with an extensive clinical evidence base. Works by stimulating insulin release, suppressing appetite, and slowing gastric emptying. Requires a prescription through a licensed provider.

View Full Intel →

A once-weekly injectable dual hormone receptor agonist targeting both GIP and GLP-1 receptors simultaneously. FDA approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The SURMOUNT trial program demonstrated up to 20.9% body weight loss — outcomes previously associated only with bariatric surgery. Prescription only.

View Full Intel →

The most advanced peptide in active clinical development on PeptideClear. A triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — producing weight loss results in Phase II trials (~24% body weight) that exceed both semaglutide and tirzepatide. Currently in Phase III trials with Eli Lilly. PeptideClear is actively tracking its path to approval.

View Full Intel →

A synthetic analog of Growth Hormone Releasing Hormone and the only GHRH analog with an FDA-approved indication. Approved under the brand name Egrifta for visceral fat reduction in HIV patients with lipodystrophy. Widely used off-label in longevity and metabolic health contexts for targeted visceral fat reduction and emerging cognitive benefits. Prescription only.

View Full Intel →

A synthetic 16 amino acid peptide fragment derived from the C-terminal domain of human growth hormone. Originally developed as an anti-obesity drug. Despite completing six human clinical trials involving over 900 participants, AOD-9604 failed to achieve statistical significance in its largest Phase IIb trial. Increasingly studied for cartilage repair. No regulatory approval.

View Full Intel →

A synthetic analog of the body's natural Growth Hormone Releasing Hormone (GHRH), comprising its first 29 amino acids. The only peptide in this catalog with prior FDA approval history, previously prescribed for pediatric growth hormone deficiency. Available through licensed compounding pharmacies by prescription. Stimulates the pituitary to produce growth hormone naturally.

View Full Intel →

A selective synthetic peptide that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin. One of the most popular peptides in longevity and performance protocols due to its clean hormonal profile. Has reached human clinical trials. Often combined with CJC-1295 for amplified effect.

View Full Intel →

A synthetic analog of Growth Hormone Releasing Hormone and one of the most widely used peptides in the longevity and performance communities. Exists in two distinct forms frequently confused — with DAC (multi-day half-life via albumin binding) and without DAC (similar to Sermorelin). Most commonly combined with Ipamorelin for synergistic GH release. Research compound only.

View Full Intel →

An orally active non-peptide compound that mimics ghrelin to stimulate sustained growth hormone and IGF-1 release. The only compound in this catalog that achieves growth hormone secretagogue effects without injection. Has reached Phase II human clinical trials for muscle wasting and hip fracture recovery. Sold as a research compound, not FDA approved.

View Full Intel →

A synthetic hexapeptide and modified derivative of GHRP-6 in which tryptophan was substituted with the more stable 2-methyl-tryptophan. Among the most potent GH secretagogues studied. Distinct from other GH compounds for its cardioprotective mechanism via CD36 receptor activation — independent of GH release entirely. Desensitization with chronic use requires cycling. Research compound only.

View Full Intel →

A 344-amino acid glycoprotein that acts as a natural antagonist of myostatin — the body's primary brake on muscle growth. By binding and neutralizing myostatin and activin, Follistatin-344 removes the inhibitory signal on muscle fiber development. Compelling animal data. Early human gene therapy trials for muscular dystrophy only. Not approved for general use.

View Full Intel →

A synthetic peptide studied in animal models for tendon repair, gut healing, and anti-inflammatory effects. Derived from a protein found in gastric juice. Shows remarkable healing properties across tendons, gut lining, and nervous system in animal studies. No human RCT data currently available. Widely used in the research community. Sold as a research compound only.

View Full Intel →

A synthetic peptide derived from Thymosin Beta-4, a protein naturally present in human cells. Studied in animal models for muscle and tendon repair, wound healing, and cardiac tissue recovery. Widely used alongside BPC-157 as a recovery stack in the biohacking community. No human clinical trials completed to date.

View Full Intel →

A synthetic tripeptide derived from the C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH). Unlike most peptides in this catalog which stimulate or build, KPV is primarily a regulator — it quiets overactive inflammatory responses without broadly suppressing immune function. Most studied for gut inflammation, wound healing, and antimicrobial activity. One of the four components of the KLOW recovery stack.

View Full Intel →

A synthetic peptide commercially known as Matrixyl, purpose-built for skincare. Works as a matrikine, mimicking a collagen breakdown signal that triggers fibroblasts to produce new collagen, elastin, and hyaluronic acid. One of the most widely used and well-studied peptides in the global skincare industry with strong human evidence for wrinkle reduction and skin firmness. Safe for use during pregnancy.

View Full Intel →

A naturally occurring copper-bound tripeptide first isolated from human plasma in 1973, with levels declining significantly with age. Stimulates collagen and elastin synthesis, promotes wound healing, and demonstrates gene expression resetting properties in aging cells. The only peptide in this catalog that spans both mainstream OTC skincare and the gray zone research community.

View Full Intel →

The most abundant protein in the human body and the best-studied peptide supplement in this catalog. Derived from bovine or marine sources and hydrolyzed for absorption. Strong human RCT evidence for skin elasticity, joint comfort, nail strength, and bone density support. Widely available OTC as a powder, capsule, or liquid with an excellent safety profile.

View Full Intel →

The second most abundant collagen in the body, found alongside Type I in skin, blood vessels, and internal organs. Almost always consumed as part of a Type I and III bovine collagen blend. Supports skin firmness, vascular integrity, and gut lining health. Less independently studied than Type I but shares a robust combined evidence base.

View Full Intel →

A synthetic hexapeptide that partially inhibits the SNARE complex to reduce facial muscle contractions — marketed as a topical alternative to botulinum toxin. Among the most commercially prevalent cosmeceutical peptides globally. Human RCT evidence exists but is limited in sample size and largely developer-funded. Effect magnitude is significantly weaker than injectable botulinum toxin.

View Full Intel →

A Lipotec-developed cosmeceutical pentapeptide that mimics enkephalin activity to dampen nerve signaling at the neuromuscular junction, reducing expression-driven wrinkle depth. Best-evidenced in combination with Argireline (marketed as Argirelox), where the two compounds target the same acetylcholine pathway at distinct binding sites for a synergistic effect. Human evidence exists but is thin and developer-dependent.

View Full Intel →

A synthetic heptapeptide derived from the 4-7 fragment of adrenocorticotropic hormone, with a stabilizing Pro-Gly-Pro tail. Developed in Russia in the 1980s. Registered as a prescription medicine in Russia for ischemic stroke and optic nerve disorders. Widely used in the nootropic community for cognitive enhancement, neuroprotection, and focus. Research compound in all Western markets.

View Full Intel →

A synthetic heptapeptide derived from Tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G, extended with a Pro-Gly-Pro stabilizing tail. Developed by the same Russian team as Semax. Registered in Russia for anxiety disorders. Demonstrates anxiolytic effects comparable to benzodiazepines without sedation or dependence risk. The calming counterpart to Semax's stimulating nootropic profile.

View Full Intel →

A naturally occurring 24 amino acid peptide encoded by mitochondrial DNA, discovered in 2001 from an Alzheimer's patient's brain. A potent suppressor of neuronal death induced by multiple familial Alzheimer's disease genes. Circulating levels decline with age. Studied for neuroprotection, Alzheimer's disease, cardiovascular protection, and longevity. No human clinical trials completed.

View Full Intel →

A naturally occurring nonapeptide first isolated from rabbit brain in 1977. Produced in the hypothalamus with marked diurnal variation. A small human study showed intravenous DSIP increased total sleep time by 59% without classical sedation. Studied for slow-wave sleep promotion, GH stimulation, and stroke recovery. The mechanism remains incompletely characterized after nearly 50 years of research.

View Full Intel →

A synthetic analog of angiotensin IV developed at Washington State University. Orally bioavailable and blood-brain barrier permeable — rare properties for a peptide. Seven orders of magnitude more potent than BDNF in synaptogenesis assays. Activates the HGF/c-Met pathway to drive formation of new synaptic connections. No human clinical trials completed. The most potent and least safety-characterized nootropic compound in this catalog.

View Full Intel →

A 16 amino acid peptide encoded by mitochondrial DNA — one of only two mitochondrial-derived peptides in this catalog. Discovered in 2015 at USC. Levels decline with age and increase with exercise. Studied for metabolic regulation, insulin sensitivity, longevity, and cardiovascular protection. Considered an exercise mimetic. No human clinical trials completed.

View Full Intel →

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian gerontologist Vladimir Khavinson as a synthetic analog of a bovine pineal gland extract. The most ambitious claim in the catalog — that four amino acids can activate telomerase, elongate telomeres, and restore pineal melatonin production. Three decades of primarily Russian research support a genuine mechanistic case. Western independent replication remains limited.

View Full Intel →

A naturally occurring dipeptide found in high concentrations in muscle and brain tissue, first discovered in 1900. Works through four distinct mechanisms — pH buffering, antioxidant activity, anti-glycation, and heavy metal chelation. Strong human RCT evidence for athletic endurance, skin anti-aging, cognitive protection, and blood sugar regulation. OTC with over 120 years of research history.

View Full Intel →

A synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation. Research focuses on neuroprotection, antioxidant activity, and cognitive preservation in aging models. Evidence is preclinical and originates almost entirely from one research institution. No independent human trials. Shares the same Russian literature caveats as Epitalon and Semax.

View Full Intel →

A direct precursor to NAD+, the coenzyme central to cellular energy production, DNA repair, and aging biology. NAD+ declines with age across tissues. Multiple human RCTs confirm oral NMN reliably raises blood NAD+ levels. Whether elevated NAD+ translates to meaningful anti-aging outcomes remains an open question — the mechanism is solid, the clinical evidence is early. OTC supplement, widely available.

View Full Intel →

A mitochondria-targeting tetrapeptide that selectively concentrates in the inner mitochondrial membrane and stabilizes cardiolipin — a phospholipid essential for electron transport chain function. One of the few compounds in the Longevity category to reach Phase III clinical trials. The pivotal MMPOWER-3 trial failed its primary endpoints in primary mitochondrial myopathy; Barth syndrome data (TAZPOWER) showed meaningful 48-week benefit. Strong foundational science, mixed human translation.

View Full Intel →

A naturally occurring thymic peptide first isolated in 1977. The synthetic form — thymalfasin — is approved in over 35 countries for chronic hepatitis B, hepatitis C, and as an immune adjuvant. Over 30 published RCTs and 11,000+ trial subjects make it one of the most clinically validated immunomodulatory peptides in existence. Activates TLR2 and TLR9 to drive T-cell maturation and NK cell activation.

View Full Intel →

The only known member of the cathelicidin family of antimicrobial peptides expressed in humans. Naturally produced by neutrophils and epithelial cells as frontline defense against infection. Effectively combats over 38 bacteria, 16 fungi, and 16 viruses through direct membrane disruption — a mechanism that is extraordinarily difficult for pathogens to develop resistance to. No FDA approval. Active clinical trials for wound healing.

View Full Intel →

A synthetic cyclic heptapeptide and melanocortin receptor agonist. FDA approved in June 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women — the only peptide in this catalog targeting sexual health. Unlike PDE5 inhibitors which work on blood vessels, PT-141 works centrally through the nervous system via MC4R activation to increase sexual desire. Prescription only.

View Full Intel →

A synthetic analog of alpha-MSH that activates melanocortin receptors for both skin tanning (MC1R) and sexual arousal (MC4R). The direct precursor to FDA-approved PT-141 — development was abandoned before Phase III. No regulatory approval anywhere. Sold as a grey-market research chemical with documented safety concerns including mole darkening and cardiovascular effects.

View Full Intel →

A hypothalamic neuropeptide hormone with one of the longest clinical histories of any compound in the catalog — FDA-approved for decades for labor induction and postpartum hemorrhage. Community interest centers on intranasal oxytocin for social cognition, bonding, and anxiety reduction. Dozens of RCTs exist; results are mixed. Funding independence is a genuine strength — this literature is almost entirely academic. A compound where the mechanism is unimpeachable and human outcome data hasn't fully kept pace.

View Full Intel →

A naturally occurring plant-derived ecdysteroid extracted from Ajuga turkestanica, popularized as a natural alternative to anabolic steroids. Does not appear to bind androgen receptors and is not expected to cause hormonal suppression. Human evidence base is currently very limited and does not match the boldness of mainstream fitness claims.

View Full Intel →

A synthetic small-molecule pan-agonist of estrogen-related receptors (ERRα, β, γ) developed at Saint Louis University. Activates the same mitochondrial and metabolic gene programs triggered by aerobic exercise — in preclinical models only. No human trials completed. Among the most discussed exercise mimetics in current research. NIH-funded independent research.

View Full Intel →

A small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) being researched for fat loss and metabolic optimization. Preclinical data shows fat cell shrinkage and reduced adiposity without changes in food intake. No completed human trials. Emerging human clinical trial activity as of 2026. Research compound only.

View Full Intel →